Drugs / DSP-0546LP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06460064 | Jun 2024 → Mar 2026 | influenza | Sumitomo Pharma Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-02-26 | Sumitomo Pharma America, Inc. | Results Interim Analysis (Cross‑Reactivity) of Phase 1 Clinical Study in Europe on Novel Universal Influenza Vaccine Candidate Formulated with Sumitomo Pharma’s Proprietary TLR7 Adjuvant (DSP-0546) sumitomo-pharma.com ↗
Sumitomo Pharma and NIBN announce the interim analysis results of the Phase 1 clinical study in Europe (the “Study”) on “fH1/DSP-0546LP” (the “Formulation”), a universal influenza vaccine candidate, for which initiation was announced on May 14, 2024. |
| 2025-10-01 | Sumitomo Pharma America, Inc. | Results Academic Conference Presentation on the Results of Phase 1 Clinical Study in Europe on a Novel Universal Influenza Vaccine Candidate Formulated with Sumitomo Pharma’s Proprietary TLR7 Adjuvant (DSP-0546) sumitomo-pharma.com ↗
The presentation included findings from non-clinical pharmacology studies. |
| 2025-07-31 | Sumitomo Pharma America, Inc. | Results Interim Analysis of Phase 1 Clinical Study on Novel Universal Influenza Vaccine Candidate Formulated with Sumitomo Pharma’s Proprietary TLR7 Adjuvant (DSP-0546) sumitomo-pharma.com ↗
The prespecified interim analysis was conducted in accordance with the protocol and confirmed generally favorable tolerability based on follow-up observations conducted up to four weeks after the final dose. |
| 2023-07-11 | Sumitomo Pharma America, Inc. | Results Elucidation of the Mode of Action of Novel Universal Influenza Vaccine Candidates sumitomo-pharma.com ↗
The results of this study were published online in the international academic journal Vaccine on June 15, 2023. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-02-26 | Sumitomo Pharma America, Inc. | Interim Analysis (Cross‑Reactivity) of Phase 1 Clinical Study in Europe on Novel Universal Influenza Vaccine Candidate Formulated with Sumitomo Pharma’s Proprietary TLR7 Adjuvant (DSP-0546) sumitomo-pharma.com ↗ |
| 2025-10-01 | Sumitomo Pharma America, Inc. | Academic Conference Presentation on the Results of Phase 1 Clinical Study in Europe on a Novel Universal Influenza Vaccine Candidate Formulated with Sumitomo Pharma’s Proprietary TLR7 Adjuvant (DSP-0546) sumitomo-pharma.com ↗ |
| 2025-07-31 | Sumitomo Pharma America, Inc. | Interim Analysis of Phase 1 Clinical Study on Novel Universal Influenza Vaccine Candidate Formulated with Sumitomo Pharma’s Proprietary TLR7 Adjuvant (DSP-0546) sumitomo-pharma.com ↗ |
| 2023-07-11 | Sumitomo Pharma America, Inc. | Elucidation of the Mode of Action of Novel Universal Influenza Vaccine Candidates sumitomo-pharma.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DSP-0546LP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06460064 ↗ |